- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06224842
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
A Phase Ib/II Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Chang Xue
- Phone Number: +86 17152776860
- Email: xuechang91@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Recruiting
- Hubei Cancer Hospital
-
Contact:
- Huijing Wu
- Phone Number: +86 13986195042
- Email: whjky122634@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient fully understands this study and voluntarily participates,willingly chooses to participate, and signs the informed consent form (ICF), expressing the willingness to comply with and having the capability to complete all trial procedures;
- Male or female patients aged 18 to 75(including 18 and 70 years old);
- ECOG score 0-2 points;
- Angioimmunoblastic T-cell lymphoma (AITL) confirmed by histopathology;
- Relapsed/refractory patients who have received at least first-line anthracyclines containing systematic therapy in the past. Relapsed lymphoma refers to lymphoma that relapses after obtaining a complete response (CR) or partial response(PR) after initial therapy.Refractory lymphoma is defined as progressive disease in the first chemotherapy cycle 2, or stable disease in the first chemotherapy cycle 4;
- There must be at least one measurable lesion that meets the Lugano2014 standard: a lymph node lesion, with a measurable lymph node length greater than 1.5cm in diameter; Non lymph node lesions, measurable extranodal lesions with a length diameter greater than 1.0cm;
During patient screening, laboratory tests must meet the following requirements, and the patient should not have received any hematopoietic growth factors, platelet, or granulocyte transfusions within the 7 days prior to the hematological assessment during screening:
- neutrophil count ≥ 1.5 x 10^9/L, it can be relaxed to ≥ 1.0 x 10^9 /L in patients with bone marrow involvement;
- hemoglobin ≥ 90 g/L(without red blood cell transfusion within 14 days), it can be relaxed to ≥ 75 g/L in patients with bone marrow involvement;
- platelet count ≥ 75 x 10^9 /L, it can be relaxed to ≥ 50 x 10^9 /L in patients with bone marrow involvement;
- Total bilirubin ≤ 1.5 times the upper limit of normal value (≤ 3 times the upper limit of normal value for patients with liver invasion);
- AST and ALT ≤ 2.5 times the upper limit of normal values ,≤ 5 times the upper limit of normal values for patients with liver invasion;
- Serum creatinine ≤ 1.5 times the upper limit of normal value; 8.Qualified patients of reproductive capability (both males and females) must agree to use a reliable contraceptive method with their partners during the trial and for at least 7 months after the last dose of medication. Female patients of childbearing age must have a negative blood pregnancy test within 7 days prior to enrollment.
Exclusion Criteria:
- Central nervous system (CNS) involvement or patients with hemophagocytic syndrome.
- History of allergy to similar drugs and excipients of the investigational drug.
Patients with the following conditions in their history of prior antitumor therapy:
- Patients previously treated withMitoxantrone liposome in combination with Azacitidine (patients who have received either of the treatments, or those who have received both treatments sequentially, are eligible).
- Previous treatment with adriamycin or other anthracyclines, with a total cumulative dose of adriamycin ≥ 350 mg/m2 (conversion for other anthracycline-type drugs: 1 mg of daunorubicin/pirarubicin/epirubicin is equivalent to 0.5 mg of adriamycin, and 1 mg of idarubicin is equivalent to 2 mg of anthracycline).
- Receipt of cytotoxic chemotherapy, radiotherapy, targeted therapy within 4 weeks, immunomodulators (thalidomide, lenalidomide) within 3 weeks, or hormonal or herbal therapy for lymphoma within 2 weeks before the first dose of the investigational drug.
- Participation in other clinical trials and use of investigational drug treatment within 4 weeks before the first dose of the investigational drug.
- History of allogeneic hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation within the past 6 months.
- Unresolved toxic reactions from prior anti-tumor therapy with toxicity persisting at > Grade 1, excluding alopecia and pigmentation.
Impaired cardiac function or significant cardiac diseases, including but not limited to:
- Occurrence of myocardial infarction, congestive heart failure, or viral myocarditis within the past 6 months before screening;
- Symptomatic cardiac diseases requiring treatment intervention, such as unstable angina, arrhythmias, etc.;
- New York Heart Association (NYHA) functional class II-IV;
- Cardiac ejection fraction (EF) detected by echocardiography below 50% or below the lower limit of the laboratory reference range at the research center;
- Ongoing history of myocarditis;
- QTc > 450 milliseconds or congenital QT interval prolongation syndrome.
- Active hepatitis B (HBV surface antigen positive and HBV-DNA titer > 2000 IU/ml) or hepatitis C (HCV antibody positive and HCV-RNA titer higher than the upper limit of the normal range at the research center).
- History of severe autoimmune diseases, immunodeficiency diseases, including HIV antibody positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
- History of malignant tumors within the past 5 years (excluding cured skin basal cell carcinoma and in situ cervical carcinoma).
- Underwent major surgery within the past 6 weeks or is expected to undergo major surgery during the study period.
- Uncontrolled hypertension (defined as blood pressure reaching stage 3 hypertension standards despite antihypertensive treatment, with systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg), or type 2 diabetes patients whose blood pressure cannot be controlled with oral hypoglycemic drugs and insulin therapy.
- Active bleeding history within the past 3 months before screening.
- History of mental illness or abuse and dependence on psychiatric drugs.
- Pregnant or lactating women.
- Other situations deemed unsuitable for participation in this study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mitoxantrone liposome and azacitidine treatment
In the dose escalation phase, the mitoxantrone liposome will start at a dose of 16 mg/m^2 on day1 via intravenous infusion, combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Three predetermined dose groups for mitoxantrone liposome are 16, 18, and 20 mg/m^2.
In the dose expansion phase, 10-20 cases will be included with the mitoxantrone liposome injection at the recommended phase II dose (RP2D) based on the results of the dose escalation phase.
|
The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Through study completion, an average of 2 year.
|
The incidence and severity of treatment-emergent adverse events
|
Through study completion, an average of 2 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Through study completion, an average of 2 year.
|
the percentage of patients who achieve complete response or partial response.
|
Through study completion, an average of 2 year.
|
Progression-Free Survival(PFS)
Time Frame: Through study completion, an average of 2 year.
|
The time from the initiation of treatment until disease progression.
|
Through study completion, an average of 2 year.
|
Overall Survival(OS)
Time Frame: Through study completion, an average of 2 year.
|
The time from the start of treatment until the patient's death from any cause.
|
Through study completion, an average of 2 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Huijing Wu, Hubei Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphadenopathy
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Immunoblastic Lymphadenopathy
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Azacitidine
- Mitoxantrone
Other Study ID Numbers
- MitAITL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioimmunoblastic T-cell Lymphoma
-
Navy General Hospital, BeijingChinese PLA General HospitalRecruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaChina
-
The Lymphoma Academic Research OrganisationCelgeneActive, not recruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaFrance, Denmark, United Kingdom, Austria, Belgium
-
Sun Yat-sen UniversityNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
Ruijin HospitalActive, not recruitingAngioimmunoblastic T-cell LymphomaChina
-
Peking Union Medical College HospitalBeijing Longfu HospitalNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
University of NebraskaNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell LymphomaUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditionsUnited States
-
Ou Bai, MD/PHDSecond Hospital of Jilin University; China-Japan Union Hospital, Jilin UniversityRecruitingAngioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedChina
-
Qingdao UniversityUnknownAngioimmunoblastic T-cell LymphomaChina
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
Clinical Trials on mitoxantrone liposome 16 and azacitidine
-
Second Affiliated Hospital, School of Medicine,...Ningbo No. 1 Hospital; Jinhua Central Hospital; Huizhou Municipal Central HospitalRecruiting
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Zhongnan HospitalShanxi Province Cancer Hospital; Ruijin Hospital; The First Affiliated Hospital... and other collaboratorsRecruitingAcute Myeloid LeukaemiaChina
-
Beat AML, LLCRecruitingPreviously Untreated Acute Myeloid LeukemiaUnited States
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaChina
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Second Affiliated Hospital of Soochow UniversityThe Affiliated Hospital of Xuzhou Medical UniversityRecruitingRelapsed/Refractory Multiple MyelomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedAdvanced Gastric CarcinomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Suspended